Emergent BioSolutions
400 Professional Drive
Suite 400
Gaithersburg
Maryland
20879
United States
Tel: 240-631-3200
Fax: 240-631-3203
Website: https://www.emergentbiosolutions.com/
About Emergent BioSolutions
Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information visit www.emergentbiosolutions.com. Find us on LinkedIn and follow us on Twitter.
Stock Symbol: EBS
574 articles about Emergent BioSolutions
-
Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B
9/14/2021
Emergent BioSolutions Inc. (NYSE:EBS) and Providence Therapeutics today announced they have entered into a five-year contract development and manufacturing (CDMO) services agreement spanning Emergent’s integrated capabilities, including development services, bulk drug substance formulation and drug product manufacturing, to support Providence’s COVID-19 messenger RNA (mRNA) vaccine development
-
Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Evaluated in NIH-Sponsored Phase 3 Clinical Trial (INSIGHT-012) of Hyperimmune Intravenous Immunoglobulin for Outpatient Treatment of COVID-19
8/25/2021
Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 3 clinical trial that will evaluate its investigational SARS-CoV-2 Immune Globulin Intravenous (Human) (COVID-HIG) plasma-derived therapy as a potential outpatient treatment for patients with coronavirus disease (COVID-19) that are at high risk of progression to severe disease.
-
Emergent BioSolutions to Participate in Investor Conferences - Aug 23, 2021
8/23/2021
Emergent BioSolutions Inc. announced that members of the company’s senior management team will participate in the following investor conferences:.
-
Emergent BioSolutions has approval to resume manufacturing vaccines, but its lawsuit issues haven’t gone away as easily.
-
Emergent BioSolutions to Resume Manufacturing Covid-19 Vaccine at Bayview Facility
7/29/2021
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) is allowing Emergent’s Bayview manufacturing facility to resume production of Johnson & Johnson’s (J&J) Covid-19 vaccine bulk drug substance.
-
COVID News: EUA Expanded for Baricitinib, Emergent Starts to Manufacture J&J Vaccine Again and More
7/29/2021
As COVID-19 infections continue to increase in the U.S., the FDA has expanded the EUA for Eli Lilly’s monoclonal antibody to include treatment with or without remdesivir. -
A recent report suggests that cross-contamination is not all that uncommon of an issue, and maybe inevitable.
-
Emergent BioSolutions to Release Second Quarter 2021 Financial Results and Conduct a Conference Call on July 29, 2021
7/15/2021
Emergent BioSolutions Inc. will host a conference call on Thursday, July 29, 2021 at 5:00 pm eastern time to discuss the financial results for the second quarter of 2021, recent business developments, revenue guidance for the third quarter of 2021, and financial outlook for full year 2021.
-
Following a manufacturing mistake that left Emergent BioSolutions with a botched batch of Johnson & Johnson’s COVID-19 vaccine, Emergent is now facing a shareholder lawsuit accusing the company of insider trading.
-
Continuing studies and news about COVID-19 around the world keeps coming in. Here’s a look.
-
COVID-19 Vaccine Drug Substance Manufactured by Emergent BioSolutions Authorized as Part of Johnson & Johnson’s Emergency Use Authorization
6/11/2021
Emergent continues to work with the FDA to address identified observations at Bayview facility in order to release additional batches and resume production .
-
Emergent said the vaccine candidate against the mosquito-borne illness showed an increase in immune response as measured by anti-chikungunya virus SNA.
-
Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus Virus-Like Particle Vaccine Candidate
5/26/2021
A dose-related increase in immune response, as measured by anti-chikungunya virus serum neutralizing antibodies (SNA), was previously observed.
-
The House Select Subcommittee on the Coronavirus Crisis questioned executives from Emergent BioSolutions as part of a congressional probe.
-
Emergent company executives Fuad El-ibri and Robert Kramer will be testifying before a congressional probe after a botched batch of 15 million doses of J&J’s COVID-19 vaccine.
-
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 20, 2021 at 9:00am EDT
5/6/2021
Emergent BioSolutions Inc. announced that its 2021 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 20, 2021 at 9:00 AM EDT.
-
Emergent BioSolutions to Participate in Investor Conferences - May 05, 2021
5/5/2021
Emergent BioSolutions Inc. announced that members of the company’s senior management team will participate in the following investor conferences:.
-
Please check out the biopharma industry's COVID-19 stories that are trending for May 4, 2021.
-
Battered by vaccine manufacturing mishaps that led to the contamination of 15 million doses of the Johnson & Johnson vaccine, Emergent BioSolutions is shaking up its leadership to ensure such errors do not occur again.
-
Emergent BioSolutions Reports Financial Results for First Quarter 2021
4/29/2021
Emergent BioSolutions Inc. reported financial results for the quarter ended March 31, 2021.